drugset / Trial / NCT00957437

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

NCT00957437

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics of different extended-release formulations of AZD1305 when given as single and multiple oral doses to healthy male volunteers.

Timeline

Start
2009-08
Primary completion
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1305 Small molecule Oral

Indications

No indication recorded.